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Caffeoylquinic acids are ubiquitous phenolic compounds with several health benefits to humans and they 
have been shown to be promisinganti-HIV compounds.  In this work, molecular docking was used to study 
the inhibition of HIV-I integrase and protease using caffeoylquinic acids. It was possible to establish that the 
naturally occurring caffeoylquinic acids are not suitable as inhibitors for protease but are very good 
inhibitors for integrase. A new binding site was found for 3, 4-O-di-Caffeoylquinic acid between the chains of 
HIV-I integrase that could possibly lead to a disruption of the catalytic process of HIV-I integrase. 
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INTRODUCTION 
Caffeoylquinic acids (CQAs) are esters of caffeic 
and quinic acid. These hydroxycinnamates have 
drawn a lot of research attention in applications 
related to diabetes(1,2), cancer(3,4) and cardio-
vascular diseases(5,6).  In the 80s, CQAs were 
considered a novel family of anti-viral 
compounds(7) and  much research was performed 
on their anti-HIV properties during the 90s(8–10). 
Recently, the interest in  the mechanism of action of 
these substances  over HIV has reappeared (11). 
HIV-I protease (EC 3.4.23.16) is a key 
therapeutic target against HIV-I and, since its 
structure was discovered, FDA has approved ten 
inhibitors(12). Most of the inhibitors for proteases are 
modified peptides or peptide-like. Tipranavir® is the 
only FDA approved protease inhibitor that does not 
have a peptide scaffold. In addition to the low oral 
bioavailability and fast excretion, these inhibitors are 
becoming less effective with the emergence of 
drug resistant HIV (13). The design of new inhibitors is 
moving from these towards macro-cyclic molecules 
that retain the geometry of a β-strand (protease’s 
substrate) but without the peptide nature (13,14) in 
the hope that these new drugs will be able to 
overcome the many drug resistance mutations of 
HIV-I (15). 
HIV-I integrase ensures that the genetic 
material of HIV is inserted into the genetic material 
of the host. Inhibiting it would prevent this from 
happening. In 1999,Zhu et al.(16) established that 
dicaffeoylquinic acids (diCQAs) could inhibit HIV-I 
integrase in an irreversible manner. They were also 
able to demonstrate that diCQAs were 
noncompetitive inhibitors of HIV-I integrase and 
several other Integrase enzymes. In 2010,Hu et 
al.(17) reported that 3, 4-O-diCQA had two possible 
binding mechanisms on HIV-I integrase. One of the 
binding sites was the active site of HIV-I integrase 
and the other binding site was in a pocket on the 
other side of the flexible loop that contains the 
catalytic residues. According to Hu et al., by 
binding at this site, 3, 4-O-diCQA would change the 




To perform the experimental work, the crystal 
structures of HIV-I protease and integrase were 
downloaded from the PDB website (ids: 1HXB and 
3AO3 respectively). 
The published crystal structure for protease 
refers to the enzyme containing the inhibitor 
Saquinavir and the crystal structure for the integrase 
contains a novel inhibitor referred to as 3-(1,3-
benzodioxol-5-yl)-1-methyl-1H-pyrazole- 5-carboxylic 
acid. The conformations of each inhibitor were 
reproduced using AutoDockVina(18) and their 
binding affinity was used as control/base value to 
compare with the CQAs. 
Molecules of severaldiCQAs(1,3-, 1,5-, 3,4-, 
3,5- and 4,5-diCQA) were created and optimized 
using the MM+ force field to an RMS below 
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0.01kcal/mol. The molecule of 5-O-CQA was also 
used. 
Three types of docking were used on this 
study. In rigid docking, the possible binding 
conformations of a ligand (small molecule) in a 
specific area of the receptor are evaluated by 
rotating its bonds and translating the molecule. 
Flexible docking is similar to rigid docking in the 
sense that the search area is specific but on this 
type of docking, several amino acid residues 
possess rotational freedom (several bonds can 
rotate). The rotation of the amino acids allows to 
reproduce more closely the accommodation of 
ligands when they bind to their target and also 
makes it possible to optimize results from rigid 
docking. Finally, blind docking has no flexibility on 
the amino acid residues but the search area 
includes the entire receptor. This type of docking is 
used to find the most likely place for a ligand to 
bind to the receptor, it is very useful to confirm 
results from other dockings or to find the binding site 
of a new ligand without the location bias of the rigid 
docking.  




The docking studies for HIV-I protease show that 
diCQAs will preferably bind to the same site as the 
commercial inhibitor Saquinavir®(fig 1 and 2) but 
with an affinity that was only 50-60% of the 
commercial product (fig 3). 
Out of the analyzed CQAs, 1,3- and 1,5-
diCQA had very similar conformations (fig 2 a). In 
addition, the 5’ branch of 3,5-diCQA and 5-CQA 
also had similar conformations, differing only on the 
3-caffeoyl moiety position (fig 2 c). Both the rigid 
and the blind docking results show that the CQA 
that binds better to HIV-I protease (i. e. has the most 
negative affinity) is 3,5-diCQA as it is shown by the 
graph on fig 3. This indicates that, out of all the 









Fig. 2 a, b and c: Binding of CQAs to HIV-I protease, a)a:1,3-diCQA 
(red) and1,5-diCQA (green), b) 3,5-diCQA (yellow) and , c) 4,5-
diCQA (magenta) and 3,4-diCQA (cyan) 
 
As 3,4-diCQA had already been established as an 
inhibitor for HIV-I integrase and 3,5-diCQA was the 
best performing ligand against protease, these two 
were chosen to be submitted to flexible docking to 
determine if their poor affinity (compared to 
Saquinavir) could be improved.  
The affinity of all ligands docked to HIV-I 
protease can be seen on fig. 3. Even resorting to 
flexible docking, the binding affinity of 3,4 and 3,5-






Fig.3  Binding affinity of ligands regarding HIV-I Protease (kcal/mol) 
– more negative values are better. 
 
The crystal structure of HIV-I integrase had two sites 
containing the same inhibitor (3-(1,3-benzodioxol-5-
yl)-1-methyl-1H-pyrazole- 5-carboxylic acid –one on 
chain A and one on B). This inhibitor was used as a 
control to compare with the affinity of the CQAs.  
Despite the fact that both chains of the enzyme 
were symmetrical, all ligands had better binding 
affinities on the B chain site than on the A chain. 
However, the control ligand had a lower binding 
affinity on the B chain (fig. 4). Regarding the best 
scoring conformation of the blind docking, 1,3-, 3,5- 
and 4,5-diCQAs were docked at the B chain 
pocket, 1,5-diCQA was docked at the A chain 
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pocket and both 3,4-diCQA and 5-CQA  were 
docked in a new site (fig. 5). 
As it is possible to see on figure 5, while the 
inhibitor from the crystal structure of HIV-I integrase 
binds to pockets between both protein chains. The 
new binding site of 3,4-diCQA and 5-CQA is located 
at the top of the enzyme between both chains. In 
order to better visualize the binding of 3, 4-diCQA, it 
is represented by a surface wireframe. The residues 
that allow 3, 4-diCQA to bind to this novel site of 
HIV-I integrase through Hydrogen bonds are: A-Lys-
71, A-Lys103, B-Lys-103, A-Lys-173 and B-Lys-173. As 
for 5-CQA, it established Hydrogen bonds with: A-






Fig. 4 Binding affinity of ligands towards HIV-I integrase (kcal/mol) 




Fig. 5 a and b– New binding site for 3,4-diCQA (orange) and 5-CQA 
(green) on HIV-I integrase, Chain A (blue), Chain B (red), inhibitor 
from the crystal structure (cyan). 
 
DISCUSSION 
With this series of dockings it was possible to confirm 
several aspects of the works from Zhu et al.(16) and 
from Hu et al.(17). Firstly, the main finding of Zhu et 
al., was corroborated, that the inhibition of HIV-I 
integrase by diCQAs is performed in an allosteric 
site. The degree of inhibition is comparable to that 
of the control. This is corroborated even further by 
the fact that when the CQAs were docked to the 
active site region of HIV-I integrase described by 
Sotriffer  & McCammon (19) the affinity of all CQAs 
is quite low (from -5.7 to -5.2 kcal/mol – data not 
shown). 
It is clear that naturally occurring CQAs are 
poor inhibitors of HIV-I protease and this is likely due 
the fact that they do not contain any macro cycles 
or resemble the conformation of a β-strand protein. 
The results from the blind docking also support this 
as all molecules were docked with a very similar 
conformation at the active site (data not shown). 
 
CONCLUSION 
Naturally occurring caffeoylquinic acids do not 
appear to be suitable for inhibiting HIV-I protease 
but an etherification reaction between phenols 
should create a macro-cycle similar to current 
protease inhibitors.  
HIV-I integrase is inhibited by naturally 
occurring diCQAs especially 3,4 and 3,5-diCQA. A 
new possible binding site for the 3,4-diCQA and 5-
CQA was found between chain A and B. It is 
possible that, by binding here, the CQAs disrupt the 
connection between the chains of the integrase 
leading to a loss of activity. 
Considering the different results obtained in 
the several dockings that were performed in this 
work and the results from Hu et al.,(17) the best 
course of action to determine where diCQAs bind in 
HIV-I integrase would be to solve its crystal structure 
bound to several CQAs. This, of course, would be a 
challenge in itself as the crystal structure of the full-
length HIV-I integrase and its complexes with DNA 
has not been completely solved yet.  
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